Table 1. Baseline Population Characteristics for AChEI Trials

| **Medication** | **Author, year**  **USPSTF Quality Rating** | **N randomized** | **Mean Age (y)** | **% Female** | **% Non-White** | **% Institutionalized, Assisted Living** | **Mean MMSE**  **(MMSE inclusion criteria)** | **%MCI**  **% Dementia** | **Specific condition** | **Mean Education (y)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Donepezil | Doody, 2009105,106  Fair | IG: 409  CG: 412 | 70 | 46 | 13 | NR | 27.5 (24-28) | MCI: 100  Dementia: 0 | MCI | 0-7: 0.6%  8-15: 52.8%  >15: 46.5% |
| Mori, 2012107  Fair | IG1: 35  IG2: 33  IG3: 37  CG: 34 | 79 | 66 | 100 | NR | 19.6  (10-26) | MCI: 0  Dementia: 100 | DLB | NR |
| Requena, 2004108,109  Fair | IG: 30  CG: 18 | 77 | 71 | NR | NR | 20.8 (NR) | MCI: 0  Dementia: 100 | AD | NR |
| Galantamine | Auchus, 2007110  GAL-INT-26 Study  Fair | IG: 397  CG: 391 | 72 | 36 | 8 | NR | 20.3 (10-26) | MCI: NR  Dementia: 100 | VaD | NR |
| Rockwood, 2006111-114  VISTA  Fair | IG: 64  CG: 66 | 77 | 63 | NR | 0 | 20.3 (10-25) | MCI: 0  Dementia: 100 | AD (probable) | 11.0 |
| Rivastigmine | Ballard, 2008115  VantagE Study  Fair | IG: 365  CG: 345 | 73 | 38 | 18 | NR | 19.2  (10-24) | MCI: 0  Dementia: 100 | VaD (including probable) | 9.3 |
| Feldman, 2007116  Study 304  Fair | IG1: 227  IG2: 229  CG: 222 | 71 | 59 | NR | 0 | 18.6 (10-26) | MCI: NR  Dementia: 100 | AD | NR |
| Mok, 2007117  Fair | IG: 20  CG: 20 | 75 | 60 | 100 | NR | 13.2 (3-24) | MCI: NR  Dementia: 100 | VaD (subcortical) | 3.3 |
| Winblad, 2007118-127 IDEAL Study  Fair | IG1: 293  IG2: 303  IG3: 297  CG: 302 | 74 | 67 | 25 | 3 | 16.5 (10-20) | MCI: 0  Dementia: 100 | AD (including probable) | 9.9 |
| Memantine | Bakchine, 2008128  Good | IG: 318  CG: 152 | 74 | 63 | 0 | NR | 18.7 (11-23) | MCI: 0  Dementia: 100 | AD (probable) | NR |
| Ferris, 2007129  Fair | IG: 30  CG: 30 | 67 | 65 | 10 | NR | 28.8 (>26) | MCI: 100  Dementia: 0 | MCI | NR |
| Porsteinsson, 2008130  MEM-MD-12 Study  Good | IG: 217  CG: 216 | 75 | 52 | NR | 0 | 16.8 (10-22) | MCI: 0  Dementia: 100 | AD (probable) | NR |
| Saxton, 2012131  MEM-MD-71  Good | IG: 136  CG: 129 | 75 | 58 | 9 | 0 | 15.8 (10-19) | MCI: 0  Dementia: 100 | AD (probable) | 11.5 |
| Wilkinson, 2012132  Fair | IG: 134  CG: 144 | 74 | 57 | <1 | 0 | 16.9 (12-20) | MCI: 0  Dementia: 100 | AD (probable) | NR |

**Abbreviations:** AChEl = acetylcholinesterase inhibitor; AD = Alzheimer’s disease; CG = control group; DLB = dementia with Lewy bodies; IDEAL = Investigation of transDermal Exelon in Alzheimer's disease; IG = intervention group; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; Multi = multi-country; N = number; NR = not reported; US = United States; VaD = vascular dementia; y = year.